These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 16288390)

  • 1. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
    Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
    Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Community acquired pneumonia: from intravenous to oral cephalosporin sequential therapy].
    Fernández P; San Martín L
    Rev Med Chil; 2000 Mar; 128(3):267-72. PubMed ID: 10962867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
    Höffken G; Barth J; Rubinstein E; Beckmann H;
    Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
    Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
    Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
    Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
    Wenisch C; Krause R; Széll M; Laferl H
    Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.
    Paladino JA; Eubanks DA; Adelman MH; Schentag JJ
    J Am Geriatr Soc; 2007 May; 55(5):651-7. PubMed ID: 17493183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
    Ewig S; Hecker H; Suttorp N; Marre R; Welte T;
    J Infect; 2011 Mar; 62(3):218-25. PubMed ID: 21276814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
    Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
    Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.
    Ramirez JA; Srinath L; Ahkee S; Huang A; Raff MJ
    Arch Intern Med; 1995 Jun; 155(12):1273-6. PubMed ID: 7778957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
    Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
    Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
    Davis SL; Delgado G; McKinnon PS
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is azithromycin monotherapy as efficacious as cefuroxime plus erythromycin for the treatment of community-acquired pneumonia in hospitalized patients?
    See S
    J Fam Pract; 2000 Oct; 49(10):883-4. PubMed ID: 11052155
    [No Abstract]   [Full Text] [Related]  

  • 20. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
    Lloyd A; Holman A; Evers T
    Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.